Life sciences news
-
reMYND commences first-in-human trial of ReS19-T Alzheimer’s program
Thursday December 3rd 2020
Read more
-
Galapagos reports positive topline results with GLPG1205 in IPF patients in PINTA Proof-of-Concept trial
Tuesday December 1st 2020
Read more
-
Biocartis announces publication of large multi-center comparison study with Idylla™ MSI Assay showing very low failure rates and excellent concordance with reference methods
Tuesday November 17th 2020
Read more
-
First patient dosed with GLPG3667 in psoriasis patient Phase 1b trial
Tuesday November 10th 2020
Read more
-
Bone Therapeutics reaches 50% treated patients in ongoing JTA-004 Phase III pivotal knee osteoarthritis study
Tuesday October 20th 2020
Read more
-
Galapagos and Servier report topline results for ROCCELLA Phase 2 clinical trial with GLPG1972/S201086 in knee osteoarthritis patients
Friday October 16th 2020
Read more
-
Bone Therapeutics’ allogeneic cell therapy product, ALLOB, shows 90% fusion rate at 24 months in Phase IIa study in lumbar spinal fusion
Wednesday October 14th 2020
Read more
-
Phase 2B/3 Trial shows efficacy of Filgotinib for the induction and maintenance of remission in moderately and severely active Ulcerative Colitis
Tuesday October 13th 2020
Read more
-
Become a flanders.bio member
Your news here?
-
argenx presents additional Efgartigimod data from Global Phase 3 ADAPT Trial
Monday October 5th 2020
Read more
-
Galapagos announces first dosing with Toledo compound GLPG3970 in psoriasis trial
Wednesday September 30th 2020
Read more
-
Celyad Oncology announces clinical trial collaboration to evaluate CYAD-101 with KEYTRUDA® (pembrolizumab) in patients with Microsatellite Stable mCRC
Tuesday September 29th 2020
Read more
More info?
Contact us
Ellen Telleir
Communication Coordinator
